मध्यम से गंभीर सिडेनहैम कोरिया: प्रबंधन जब प्रथम-पंक्ति कॉर्टिकोस्टेरॉइड इम्यूनोथेरेपी कार्यात्मक पुनर्प्राप्ति प्राप्त नहीं कर सकी

References

• DOI: 10.1542/peds.2025-072466
• Patients with moderate and severe SC should be offered immunotherapy.
• Motor with/without behavioral or psychiatric symptoms with impact to activities of daily living, school and family life but not fulfilling criteria as in Severe Disease below.
• In moderate to severe SC and a failure of response to corticosteroid therapy, IVIG or plasma exchange can be considered as additional immunotherapy.
• Depending on severity and treatment response, prolonged use of corticosteroids may be considered, such as monthly IV methylprednisolone for 1–3 mos or oral prednisone/prednisolone for 1–3 mos.
• The main goal of management is resolution of SC symptoms and an early return to normal physical, educational, and social functioning, where possible.